Profile
Wendy E.
Rieder was the founder of Microbiotix, Inc. founded in 1998, where she held the title of COO & Vice President-Business Development in 2002.
She also held former positions as VP-Intellectual Property & Legal Affairs at Synta Pharmaceuticals Corp.
from 2002 to 2013, VP-Business Development & Intellectual Property at LipoGenics, Inc. from 1997 to 1999, Patent Agent at Fish & Neave LLP from 1991 to 1995, and Patent Attorney at Boehringer Ingelheim Pharmaceuticals, Inc. from 1995 to 1997.
Ms. Rieder's education history includes a graduate degree from The Trustees of Columbia University in The City of New York and a graduate degree from Fordham University School of Law.
Former positions of Wendy E. Rieder
| Companies | Position | End |
|---|---|---|
Microbiotix, Inc.
 Microbiotix, Inc. Pharmaceuticals: MajorHealth Technology Microbiotix, Inc. is a clinical stage biopharmaceutical company located in Worcester, MA. The private company's lead therapeutic compound, mbx-400, is a potent and novel nucleoside analog dual DNA polymerase/kinase inhibitor for the treatment of human cytomegalovirus (CMV). Microbiotix has consistently been the top recipient of NIH awards amongst biotech/pharma companies, which is a testament to their innovation. The company was founded by Wendy E. Rieder and is focused on the discovery and development of proprietary small molecule drugs that target serious infectious diseases, including multi-drug resistant pathogens. | Founder | 2002-11-30 |
LipoGenics, Inc.
 LipoGenics, Inc. Food: Meat/Fish/DairyConsumer Non-Durables Part of NutraGenics, Inc. (Arizona), LipoGenics, Inc. manufactures dietary supplements. The private company is based in Phoenix, AZ. The company was founded by Leaf Huang. LipoGenics was acquired by NutraGenics, Inc. (Arizona) on October 31, 1996. | Corporate Officer/Principal | 1999-11-30 |
Boehringer Ingelheim Pharmaceuticals, Inc.
 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Corporate Officer/Principal | 1997-06-30 |
Fish & Neave LLP
 Fish & Neave LLP Miscellaneous Commercial ServicesCommercial Services Fish & Neave operates as a law firm. It specializes in specializes in intellectual property issues involving patents, trademarks, and copyrights. The company is headquartered in New York, NY. | Corporate Officer/Principal | 1995-06-30 |
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Corporate Officer/Principal | - |
Training of Wendy E. Rieder
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Fordham University School of Law | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Health Technology |
LipoGenics, Inc.
LipoGenics, Inc. Food: Meat/Fish/DairyConsumer Non-Durables Part of NutraGenics, Inc. (Arizona), LipoGenics, Inc. manufactures dietary supplements. The private company is based in Phoenix, AZ. The company was founded by Leaf Huang. LipoGenics was acquired by NutraGenics, Inc. (Arizona) on October 31, 1996. | Consumer Non-Durables |
Fish & Neave LLP
Fish & Neave LLP Miscellaneous Commercial ServicesCommercial Services Fish & Neave operates as a law firm. It specializes in specializes in intellectual property issues involving patents, trademarks, and copyrights. The company is headquartered in New York, NY. | Commercial Services |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
Microbiotix, Inc.
Microbiotix, Inc. Pharmaceuticals: MajorHealth Technology Microbiotix, Inc. is a clinical stage biopharmaceutical company located in Worcester, MA. The private company's lead therapeutic compound, mbx-400, is a potent and novel nucleoside analog dual DNA polymerase/kinase inhibitor for the treatment of human cytomegalovirus (CMV). Microbiotix has consistently been the top recipient of NIH awards amongst biotech/pharma companies, which is a testament to their innovation. The company was founded by Wendy E. Rieder and is focused on the discovery and development of proprietary small molecule drugs that target serious infectious diseases, including multi-drug resistant pathogens. | Health Technology |
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
- Stock Market
- Insiders
- Wendy E. Rieder